These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 29052441)

  • 21. Discovery of potent and orally bioavailable indazole-based glucagon receptor antagonists for the treatment of type 2 diabetes.
    Xu G; Gaul MD; Song F; Du F; Liang Y; DesJarlais RL; DiLoreto K; Shook B; Rentzeperis D; Santulli R; Eckardt A; Demarest K
    Bioorg Med Chem Lett; 2019 Oct; 29(20):126668. PubMed ID: 31519374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glucagon receptor blockage inhibits β-cell dedifferentiation through FoxO1.
    Wang K; Cui X; Li F; Xia L; Wei T; Liu J; Fu W; Yang J; Hong T; Wei R
    Am J Physiol Endocrinol Metab; 2023 Jan; 324(1):E97-E113. PubMed ID: 36383639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetics and pharmacodynamics of IONIS-GCGR
    Luu KT; Morgan ES; Bhanot S; Geary R; Smith A; Bethune C; Watts L; Henry S; Wang Y
    J Pharmacokinet Pharmacodyn; 2017 Jun; 44(3):179-191. PubMed ID: 28132162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Identification of Novel Protein-Protein Interactions in Liver that Affect Glucagon Receptor Activity.
    Han J; Zhang M; Froese S; Dai FF; Robitaille M; Bhattacharjee A; Huang X; Jia W; Angers S; Wheeler MB; Wei L
    PLoS One; 2015; 10(6):e0129226. PubMed ID: 26075596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Application of RNA interference to improve mechanistic understanding of omics responses to a hepatotoxic drug in primary rat hepatocytes.
    Adler M; Leich E; Ellinger-Ziegelbauer H; Hewitt P; Dekant W; Rosenwald A; Mally A
    Toxicology; 2014 Dec; 326():86-95. PubMed ID: 25456269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes.
    Yang J; MacDougall ML; McDowell MT; Xi L; Wei R; Zavadoski WJ; Molloy MP; Baker JD; Kuhn M; Cabrera O; Treadway JL
    BMC Genomics; 2011 Jun; 12():281. PubMed ID: 21631939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists.
    Dallas-Yang Q; Shen X; Strowski M; Brady E; Saperstein R; Gibson RE; Szalkowski D; Qureshi SA; Candelore MR; Fenyk-Melody JE; Parmee ER; Zhang BB; Jiang G
    Eur J Pharmacol; 2004 Oct; 501(1-3):225-34. PubMed ID: 15464082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Small molecule glucagon receptor antagonists: an updated patent review (2015-2019).
    Cheng C; Jabri S; Taoka BM; Sinz CJ
    Expert Opin Ther Pat; 2020 Jul; 30(7):509-526. PubMed ID: 32552241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging GLP-1 receptor agonists.
    Lund A; Knop FK; Vilsbøll T
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):607-18. PubMed ID: 21905764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors.
    Sloop KW; Cao JX; Siesky AM; Zhang HY; Bodenmiller DM; Cox AL; Jacobs SJ; Moyers JS; Owens RA; Showalter AD; Brenner MB; Raap A; Gromada J; Berridge BR; Monteith DK; Porksen N; McKay RA; Monia BP; Bhanot S; Watts LM; Michael MD
    J Clin Invest; 2004 Jun; 113(11):1571-81. PubMed ID: 15173883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emergence of promising therapies in diabetes mellitus.
    Akkati S; Sam KG; Tungha G
    J Clin Pharmacol; 2011 Jun; 51(6):796-804. PubMed ID: 20705952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia.
    Conarello SL; Jiang G; Mu J; Li Z; Woods J; Zycband E; Ronan J; Liu F; Roy RS; Zhu L; Charron MJ; Zhang BB
    Diabetologia; 2007 Jan; 50(1):142-50. PubMed ID: 17131145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel GLP-1 receptor agonists for diabetes.
    Garber AJ
    Expert Opin Investig Drugs; 2012 Jan; 21(1):45-57. PubMed ID: 22111970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Glucagon antagonists open a new way in treatment of type 2 diabetes Mellitus].
    Vondra K
    Vnitr Lek; 2016; 62(7-8):661-6. PubMed ID: 27627094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fully human monoclonal antibodies antagonizing the glucagon receptor improve glucose homeostasis in mice and monkeys.
    Yan H; Gu W; Yang J; Bi V; Shen Y; Lee E; Winters KA; Komorowski R; Zhang C; Patel JJ; Caughey D; Elliott GS; Lau YY; Wang J; Li YS; Boone T; Lindberg RA; Hu S; Véniant MM
    J Pharmacol Exp Ther; 2009 Apr; 329(1):102-11. PubMed ID: 19129372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two novel glucagon receptor antagonists prove effective therapeutic agents in high-fat-fed and obese diabetic mice.
    O'Harte FP; Franklin ZJ; Irwin N
    Diabetes Obes Metab; 2014 Dec; 16(12):1214-22. PubMed ID: 25060150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucagon antagonism as a potential therapeutic target in type 2 diabetes.
    Bagger JI; Knop FK; Holst JJ; Vilsbøll T
    Diabetes Obes Metab; 2011 Nov; 13(11):965-71. PubMed ID: 21615669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel glucagon-like peptide-1/glucagon receptor dual agonist exhibits weight-lowering and diabetes-protective effects.
    Zhou J; Cai X; Huang X; Dai Y; Sun L; Zhang B; Yang B; Lin H; Huang W; Qian H
    Eur J Med Chem; 2017 Sep; 138():1158-1169. PubMed ID: 28772236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes.
    Lau DC; Teoh H
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S148-54. PubMed ID: 26654858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis and structure activity relationships of indazole and indole derivatives as potent glucagon receptor antagonists.
    Song F; Xu G; Gaul MD; Zhao B; Lu T; Zhang R; DesJarlais RL; DiLoreto K; Huebert N; Shook B; Rentzeperis D; Santulli R; Eckardt A; Demarest K
    Bioorg Med Chem Lett; 2019 Aug; 29(15):1974-1980. PubMed ID: 31138472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.